Novartis' (NVS) experimental drug del-desiran failed to meet its primary endpoint in a late-stage trial for type 1 myotonic dystrophy, a key asset acquired in the company's $12 billion acquisition of Avidity Biosciences. This setback comes just days after its cholesterol drug pelacarsen also failed in a late-stage study. Despite these challenges, Novartis reiterated its goal of achieving 5%-6% annual sales growth by 2030.